Stryker v. OsteoMed: Federal Circuit Affirms Bone Plate Patent Unpatentable
Stryker European Operations Holdings, LLC lost its appeal at the Federal Circuit after OsteoMed, LLC successfully challenged the validity of US9078713B2, a patent covering an orthopedic implant plate fixed between two bone parts. The Federal Circuit affirmed the unpatentability finding, ending a 688-day appellate battle and leaving Stryker’s bone plate patent protection extinguished.
Federal Circuit kills Stryker bone plate patent after OsteoMed challenge
Stryker European Operations Holdings, LLC brought this Federal Circuit appeal on 19 September 2023, seeking to overturn a prior determination that US9078713B2 — a patent claiming an orthopedic implant plate designed to be fixed between two bone parts — was unpatentable. The defendant and prevailing party, OsteoMed, LLC, had successfully challenged the patent’s validity through an invalidity/cancellation action, and the lower tribunal’s finding of unpatentability formed the sole basis of this appeal.
The Federal Circuit issued its judgment on 7 August 2025, affirming the unpatentability determination in full. An affirmance at this level means the court found no reversible error in the reasoning or conclusions of the proceeding below. With the patent now cancelled, Stryker loses the exclusive rights US9078713B2 would have conferred over the claimed bone plate technology, and OsteoMed is free to operate without the constraint of that patent.
The 688-day duration from filing to final judgment is consistent with moderately complex Federal Circuit appeals involving patentability disputes. The public record does not disclose the specific grounds of unpatentability — whether obviousness, anticipation, or another basis — nor whether Stryker has pursued or intends to pursue further review. The outcome suggests OsteoMed mounted a technically and legally compelling invalidity case that withstood full appellate scrutiny.
Filing to Unpatentable in 688 days
688 days from filing to Federal Circuit decision — above median for PTAB-origin appeals
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower ruling stands without reversible error
When the Federal Circuit affirms, it confirms that no reversible legal or factual error occurred in the proceeding below. The court does not retry the merits — it reviews whether the tribunal applied the correct legal standards and whether its findings were supported by substantial evidence. An affirmance here means the unpatentability determination survives full appellate review, making it the final word on the validity of US9078713B2 absent a successful en banc or Supreme Court petition.
No reversible error foundStryker’s bone plate patent is extinguished — enforcement rights lost
For Stryker European Operations Holdings, the affirmance is dispositive. US9078713B2 is cancelled, stripping Stryker of any exclusivity over the claimed orthopedic plate technology. Stryker cannot enforce the patent against OsteoMed or any other competitor. To reassert protection in this space, Stryker would need to rely on continuation applications, design patents, or other portfolio assets — none of which are guaranteed to cover the same commercial ground.
Patent cancelled; no enforcement pathOsteoMed secures clear freedom to operate without further appeal risk
OsteoMed’s invalidity challenge has been validated at the highest available appellate level for patent disputes. Unless Stryker petitions for en banc rehearing or seeks certiorari — both with low grant rates — the cancellation of US9078713B2 is final. OsteoMed can now develop, manufacture, and commercialise orthopedic plate products that would have been covered by the asserted claims without exposure to infringement liability under this patent.
FTO confirmed; appeal options near-exhaustedBone plate technology sector gains freedom as Stryker IP position weakens
The cancellation of a Stryker orthopedic plate patent removes a barrier that potentially restricted competitor product design in the bone fixation space. Other orthopedic device makers — particularly those designing plates fixed between two bone parts — should monitor whether Stryker pursues related claims in continuation or divisional applications. The affirmance also signals that the invalidity arguments advanced against this patent were sufficiently robust to survive Federal Circuit review, raising the evidentiary bar for similar challenges in the sector.
Competitor freedom widenedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Stryker European Operations Holdings, LLC | Company | Medical device company — holder of US9078713B2 orthopedic bone plate patentSearch in Eureka ↗ |
| Defendant | OsteoMed, LLC | Company | OsteoMed, LLC — orthopedic implant company and successful patent challengerSearch in Eureka ↗ |
| Plaintiff counsel | Robert Anthony Surrette | Attorney | Counsel for Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Scott P. Mcbride | Attorney | Counsel for Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Sean Sparrow I | Attorney | Counsel for Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Sharon Hwang | Attorney | Counsel for Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Plaintiff law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Stryker European Operations Holdings, LLCSearch in Eureka ↗ |
| Defendant counsel | Devon C. Beane | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant counsel | Jason Alexander Engel | Attorney | Counsel for OsteoMed, LLCSearch in Eureka ↗ |
| Defendant law firm | K&L Gates, LLP | Law Firm | Representing OsteoMed, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is unambiguous and final. At the Federal Circuit, affirmance requires the court to find that the tribunal below applied correct legal standards and that its factual findings were supported by substantial evidence. The terse form of the order is typical for affirmances where the court finds no error warranting extended discussion. For Stryker, this forecloses the appeal; for OsteoMed, it confirms the cancellation of US9078713B2 with maximum legal certainty.
US9078713B2 — orthopedic bone plate implant fixed between two bone segments
US9078713B2, filed under application number US14/041706, claims an orthopedic implant in the form of a plate designed to be fixed between two bone parts. This category of technology — bone fixation plates — sits at the intersection of orthopaedic surgery and biomechanical engineering, covering devices used to stabilise fractures or bridge bone segments during healing. The patent was held by Stryker European Operations Holdings, a subsidiary of Stryker Corporation, one of the largest global medical device groups. Following the Federal Circuit’s affirmance, the patent is cancelled and no longer in force.
For the orthopedic implant sector, bone plate patents represent a critical layer of competitive protection given the commercial significance of fixation hardware in trauma and reconstructive surgery. The cancellation of US9078713B2 removes a Stryker-held exclusivity position that could have been used to restrict competitor product designs. Companies developing or selling inter-bone plate systems — particularly those with structural features covered by the now-cancelled claims — should reassess their FTO positions, while noting that Stryker’s broader orthopedic portfolio may include related patents with overlapping scope.
Should you run an FTO analysis against US9078713B2 and related Stryker bone plate patents?
Any company designing, manufacturing, or distributing orthopedic fixation plates — particularly plates intended to be fixed between two bone segments — should account for the cancellation of US9078713B2 in their freedom-to-operate assessments. While this specific patent is extinguished, Stryker’s orthopedic portfolio is extensive. Continuation or divisional applications may carry forward claim language similar to the cancelled patent, and a clean FTO today can become outdated if a related application issues. R&D teams launching new bone plate products or modifying existing designs should treat this ruling as a trigger for a fresh portfolio-level FTO sweep.
PatSnap Eureka’s FTO Search Agent can map the full patent family around US9078713B2, identify any pending Stryker applications with overlapping claim scope, and flag prior art that informed the unpatentability finding. Eureka’s claim-charting tools allow product teams to test specific design features against active claims in the Stryker orthopedic portfolio — reducing the time and cost of a manual FTO analysis while surfacing risks that might otherwise be missed in a post-litigation landscape.
Run a freedom-to-operate analysis on US9078713B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit orthopedic implant patent validity appeals
Cases before the Federal Circuit involving orthopedic implant patent validity challenges — including bone plate and fixation device disputes — most relevant to the Stryker v. OsteoMed outcome.
What this case signals for the orthopedic implant IP landscape
A cancelled Stryker bone plate patent and a full Federal Circuit affirmance send a clear signal to the broader orthopedics IP community.
Invalidity at the Federal Circuit level is a durable outcome — act on it
A Federal Circuit affirmance of unpatentability carries substantial weight. Competitors and licensees in the orthopedic plate space should treat US9078713B2 as permanently extinguished unless Stryker secures en banc or Supreme Court review — historically unlikely. IP teams should update freedom-to-operate assessments to remove this patent as an active risk.
Watch Stryker’s continuation portfolio for related bone plate claims
When a parent patent is cancelled, patentees often hold or file continuation applications with overlapping claim scope. R&D and IP teams at orthopedic companies should run a forward citation and family search on US9078713B2 to identify any pending Stryker applications that could resurface similar restrictions on bone plate technology.
Stryker v OsteoMed — key questions answered
The Federal Circuit affirmed the unpatentability of Stryker’s US9078713B2 on 7 August 2025, upholding OsteoMed’s successful invalidity/cancellation challenge. The 688-day appeal ended with the bone plate patent cancelled, leaving Stryker without enforceable rights under that patent.
An affirmance by the Federal Circuit means the court found no reversible error in the unpatentability determination below. The patent is cancelled and unenforceable. Stryker’s only remaining avenues would be en banc rehearing or a petition for certiorari to the Supreme Court — both with very low success rates — meaning the cancellation is effectively final.
Stryker may hold continuation, divisional, or related applications that cover overlapping technology. The cancellation of US9078713B2 does not automatically extinguish Stryker’s entire bone plate IP position. Competitors and product teams should conduct a full patent family search to identify any related active Stryker applications before concluding the space is clear.
OsteoMed has confirmed freedom to operate with respect to the claims of US9078713B2, which are cancelled. However, a thorough FTO analysis should extend to Stryker’s broader orthopedic plate portfolio — including any pending applications with similar claim scope — before OsteoMed or third parties treat the entire technology area as unrestricted.
Stryker European Operations Holdings was represented by McAndrews, Held & Malloy Ltd., with attorneys Robert Anthony Surrette, Scott P. McBride, Sean Sparrow I, and Sharon Hwang. OsteoMed, LLC was represented by K&L Gates, LLP, with attorneys Devon C. Beane and Jason Alexander Engel.
PatSnap Eureka searches patents and litigation data to answer instantly.